Ascend Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Ascend Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-45,739	Closed	-$6.95M	–	251
2017 Q3	$6.95M	Buy	+45,739	New	+$6.88M	0.26%	97
2016 Q1	–	Sell	-50,465	Closed	-$6.35M	–	150
2015 Q4	$6.35M	Buy	+50,465	New	+$6.09M	0.22%	97

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Ascend Capital's VRTX Position: Q4 2017 in Review

Ascend Capital sold out of Vertex Pharmaceuticals (VRTX) in Q4 2017, closing a stake of 45,739 shares — an estimated $6.95M sold.

Ascend Capital first reported a position in VRTX in Q4 2015 and held it in 2 quarters. The position peaked at $6.95M in Q3 2017. 644 funds tracked by Wall St. Rank hold VRTX as of Q4 2017.

Ascend Capital reported no remaining Vertex Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
Ascend Capital sold 45,739 Vertex Pharmaceuticals shares in Q4 2017, an estimated $6.95M.
Ascend Capital first reported a position in Vertex Pharmaceuticals in Q4 2015 and held it in 2 quarters.
Ascend Capital's Vertex Pharmaceuticals position peaked at $6.95M in Q3 2017.
644 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2017.

Based on Ascend Capital's 13F filing for Q4 2017, filed 13 Feb 2018.